#United States #Dublin #Theravance Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Reports Impressive Second Quarter 2025 Results

On August 12, 2025, Theravance Biopharma, Inc. (NASDAQ: TBPH) announced its financial and operational results for the second quarter of 2025, demonstrating strong growth and significant milestones achieved during the period. The company witnessed robust commercial success driven primarily by its product YUPELRI (revefenacin) and progress in its investigational treatment, ampreloxetine. CEO Rick E Winningham expressed confidence in the company's momentum heading into the second half of the year.

Key Financial Highlights

The second quarter saw total revenues climb to $26.2 million, comprising $18.7 million from collaborations with Viatris and $7.5 million from YUPELRI's licensing revenue due to its recent Chinese regulatory approval. This marked a notable year-over-year increase, with Viatris collaboration revenue skyrocketing by 31% compared to the same quarter the previous year. Additionally, YUPELRI achieved net sales of $66.3 million in the United States, reflecting a 22% increase year-over-year.

Selling and administrative expenses were recorded at $18.4 million, up from $17.1 million in Q2 2024. Research and development expenses came in at $10.5 million, slightly higher than the previous year's $10.0 million in the same quarter. One-time cash received from the sale of royalty interest in TRELEGY ELLIPTA amounted to $225 million and was part of broader strategic efforts to enhance shareholder value.

Operational Success and Product Development

Theravance's YUPELRI inhalation solution, a novel once-daily nebulized bronchodilator, has displayed promising growth metrics in commercial segments. The 4% increase in customer demand aligned with a substantial 31% rise in hospitals' uptake compared to the previous year. The milestone payment of $7.5 million from Viatris, following YUPELRI's Chinese approval, further solidified the product's market positioning.

In terms of product development, Theravance remains focused on ampreloxetine, an investigational norepinephrine reuptake inhibitor designed for treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA). The pivotal Phase 3 CYPRESS study is nearing enrollment completion with results expected in approximately six months, putting the company in line for possible regulatory approval.

Solid Financial Position

Theravance's balance sheet remains strong, exhibiting $339 million in cash with no debt. This solidifies its capacity to continue investing in research and development as well as providing returns to shareholders through effective capital allocation strategies.

Theravance is committed to leveraging its expertise in drug development and commercialization, illustrated by its focus on YUPELRI and its late-stage candidate ampreloxetine, which has the potential to revolutionize treatment for MSA patients experiencing orthostatic hypotension.

Conclusion

As Theravance Biopharma looks ahead, its strong second-quarter performance highlights its strategic initiatives in drug commercialization and development. The company's commitment to creating shareholder value and its focus on enhancing patient care positions it well for continued success in the biopharmaceutical sector. Investors and stakeholders can expect a detailed follow-up during the investor conference call scheduled for later today at 5:00 PM ET.